Predicting response to patients with gastric cancer via a dynamic-aware model with longitudinal liquid biopsy data

Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–79.

Article  PubMed  PubMed Central  Google Scholar 

Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–36.

Article  PubMed  Google Scholar 

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.

Article  CAS  PubMed  Google Scholar 

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.

Article  PubMed  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197–208.

Article  CAS  PubMed  Google Scholar 

Yu YY, Zhu YJ, Xiao ZZ, Chen YD, Chang XS, Liu YH, et al. The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers. Biomark Res. 2022;10(1):73.

Article  PubMed  PubMed Central  Google Scholar 

Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94.

Article  CAS  PubMed  Google Scholar 

Di Capua D, Bracken-Clarke D, Ronan K, Baird AM, Finn S. The liquid biopsy for lung cancer: state of the art, limitations and future developments. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13163923.

Article  PubMed  Google Scholar 

Deng Z, Wu S, Wang Y, Shi D. Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine. 2022;83: 104237.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong X, Roh W, Sullivan RJ, Wong KHK, Wittner BS, Guo H, et al. The lipogenic regulator SREBP2 induces transferrin in circulating melanoma cells and suppresses ferroptosis. Cancer Discov. 2021;11(3):678–95.

Article  CAS  PubMed  Google Scholar 

Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, et al. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med. 2014;6(11):1371–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25(14):4255–63.

Article  CAS  PubMed  Google Scholar 

Stergiopoulou D, Markou A, Strati A, Zavridou M, Tzanikou E, Mastoraki S, et al. Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer. Sci Rep. 2023;13(1):1258.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pei H, Li L, Han Z, Wang Y, Tang B. Recent advances in microfluidic technologies for circulating tumor cells: enrichment, single-cell analysis, and liquid biopsy for clinical applications. Lab Chip. 2020;20(21):3854–75.

Article  CAS  PubMed  Google Scholar 

Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, et al. Liquid biopsies: the future of cancer early detection. J Transl Med. 2023;21(1):118.

Article  PubMed  PubMed Central  Google Scholar 

Edsjo A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix-Panabieres C, et al. Precision cancer medicine: concepts, current practice, and future developments. J Intern Med. 2023;294(4):455–81.

Article  CAS  PubMed  Google Scholar 

He S, Yu S, Wei J, Ding L, Yang X, Wu Y. New horizons in the identification of circulating tumor cells (CTCs): an emerging paradigm shift in cytosensors. Biosens Bioelectron. 2022;203: 114043.

Article  CAS  PubMed  Google Scholar 

Chiang PJ, Xu T, Cha TL, Tsai YT, Liu SY, Wu ST, et al. Programmed cell death ligand 1 expression in circulating tumor cells as a predictor of treatment response in patients with urothelial carcinoma. Biology. 2021. https://doi.org/10.3390/biology10070674.

Article  PubMed  PubMed Central  Google Scholar 

Troncarelli Flores BC, Souza ESV, Ali Abdallah E, Mello CAL, Gobo Silva ML, Gomes Mendes G, et al. Molecular and kinetic analyses of circulating tumor cells as predictive markers of treatment response in locally advanced rectal cancer patients. Cells. 2019;8(7):641.

Article  PubMed  PubMed Central  Google Scholar 

He K, Baniasad M, Kwon H, Caval T, Xu G, Lebrilla C, et al. Decoding the glycoproteome: a new frontier for biomarker discovery in cancer. J Hematol Oncol. 2024;17(1):12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lei Y, Sun N, Zhang G, Liu C, Lu Z, Huang J, et al. Combined detection of aneuploid circulating tumor-derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non-small-cell lung cancer. Clin Transl Med. 2020;10(3): e128.

Article  PubMed  PubMed Central  Google Scholar 

Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K, et al. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol. 2010;21(12):2382–9.

Article  CAS  PubMed  Google Scholar 

Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, et al. Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment. BMC Gastroenterol. 2021;21(1):283.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Machida M, Ambo M, Mishina R, Hada N, Tachibana F, Yamashita M, et al. Integrated predictors by propensity scoring with tumor markers and plasma levels of microRNA-21-5p, IL-17, and IL-10 complement early detection of hepatocellular carcinoma in patients with liver cirrhosis. Technol Cancer Res Treat. 2023. https://doi.org/10.1177/15330338231212084.

Article  PubMed  PubMed Central  Google Scholar 

Salehi M, Lavasani ZM, Keshavarz Alikhani H, Shokouhian B, Hassan M, Najimi M, et al. Circulating tumor cells as a promising tool for early detection of hepatocellular carcinoma. Cells. 2023. https://doi.org/10.3390/cells12182260.

Article  PubMed  PubMed Central  Google Scholar 

Wang HT, Bai LY, Wang YT, Lin HJ, Yang HR, Hsueh PR, et al. Circulating tumor cells positivity provides an early detection of recurrence of pancreatic cancer. J Formos Med Assoc. 2023;122(7):653–5.

Article  PubMed  Google Scholar 

Feng Z, Wu J, Lu Y, Chan YT, Zhang C, Wang D, et al. Circulating tumor cells in the early detection of human cancers. Int J Biol Sci. 2022;18(8):3251–65.

Article  CAS 

Comments (0)

No login
gif